Study Detail

SARS-COV-2 Virus Vaccine (VLA2001) against COVID-19

A Phase I/II RANDOMIZED, two parts, dose-FINDING STUDY TO evaluate THE SAFETY, TOLERABILITY and Immunogenicity OF An inactivated, AdJUVANTED Sars-Cov-2 VIRUS VACCINE CANDIDATE (VLA2001), AGAINST covid-19 IN HEALTHY Subjects

Status: In Setup

Type: Interventional

Funder: Valneva

Sponsor: Valneva

CI: Prof Adam Finn (UH Bristol)

IRAS-Number: 289098

CPMS-ID: 47465

Approval Date: 29 October 2020

Back to listing